Ownership and insider activity for Forte Biosciences, Inc. (FBRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Price
| Price | $76.99 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-27 | Kornfeld Steven | U-Tender | 3,960 | $305K |
| 2026-08-27 | Kornfeld Steven | D-Return | 1,200 | $567K |
| 2026-08-27 | Kornfeld Steven | D-Return | 800 | $711K |
| 2026-08-27 | Kornfeld Steven | D-Return | 1,000 | $32K |
| 2026-08-27 | Kornfeld Steven | D-Return | 1,000 | $20K |
| 2026-08-27 | Kornfeld Steven | D-Return | 2,000 | $17K |
| 2026-08-27 | Kornfeld Steven | D-Return | 31,000 | $234K |
| 2026-08-27 | Kornfeld Steven | D-Return | 18,353 | |
| 2026-08-27 | Brun Scott C. | D-Return | 2,000 | $50K |
| 2026-08-27 | Brun Scott C. | D-Return | 1,000 | $20K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.5M | $35.9M | $40.8M | $6.9M | $58.8M | $42.0M | $41.1M | $12.0M | $22.2M | $77.0M |
| Short-term Investments | $25.7M | $52.8M | $55.3M | 0 | 0 | 0 | 0 | $25.2M | $36.1M | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $817000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $32.5M | $90.6M | $97.7M | $7.5M | $59.9M | $42.5M | $41.5M | $38.3M | $61.3M | $80.6M |
| Property, Plant & Equipment | $743000 | $1.2M | $4.0M | $152000 | $97000 | 0 | 0 | $109000 | $77000 | $129000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $35.4M | $92.1M | $103.1M | $7.7M | $61.2M | $43.3M | $42.0M | $39.0M | $61.6M | $82.8M |
| Accounts Payable | $1.7M | $2.0M | $78379 | $1.6M | $1.2M | $946000 | $1.2M | $1.4M | $4.9M | $10.0M |
| Short-term Debt | $7.2M | $7.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $14.4M | $17.3M | $16.5M | $1.9M | $2.3M | $1.8M | $3.2M | $3.7M | $9.1M | $20.8M |
| Long-term Debt | $13.8M | $3.6M | $26.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $28.4M | $21.0M | $44.9M | $1.9M | $2.3M | $1.8M | $3.2M | $3.7M | $9.1M | $21.8M |
| Retained Earnings | -$128.0M | -$166.9M | -$215.9M | -$5.0M | -$51.5M | -$73.2M | -$87.0M | -$118.5M | -$154.0M | -$223.4M |
| Total Equity | $7.0M | $71.1M | $58.1M | $5.7M | $59.0M | $41.5M | $38.8M | $35.3M | $52.5M | $61.0M |
| Total Debt | $21.0M | $10.8M | $26.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$10.3M | -$77.9M | -$69.9M | -$6.9M | -$58.8M | -$42.0M | -$41.1M | -$37.1M | -$58.4M | -$77.0M |
| Working Capital | $18.1M | $73.3M | $81.2M | $5.6M | $57.6M | $40.8M | $38.3M | $34.7M | $52.3M | $59.8M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 10.01 |
Profitability
| Return on Equity | -94.82% |
| Return on Invested Capital | -48.53% |
| Return on Assets | -42.74% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · ALEC · APLT · CRBP · CRDF · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of FBRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks